Pharmacological Institute, College of Medicine, National Taiwan University, No.1, Jen-Ai Road, Sec. 1, Taipei 10051, Taiwan.
Chembiochem. 2012 Jul 23;13(11):1663-72. doi: 10.1002/cbic.201200191. Epub 2012 Jul 3.
Over the past several decades, there has been a considerable and still growing interest in discovering natural products with anticancer potential from traditional Chinese medicine and increasing their anticancer selectivity by chemical modification. In addition, total synthesis of active compounds from natural products can overcome problems related to poor resource availability. DYZ-2-90 is a novel ring-opened compound modified from neo-tanshinlactone, which is isolated from Chinese medicinal herb tanshen. Both in vitro and in vivo tubulin polymerization assays showed that DYZ-2-90 directly bound to microtubules and rapidly induced tubulin depolymerization, inducing ERK-mediated mitotic arrest and subsequent apoptosis by JNK activation in cancer cells, respectively. These results suggest that the fate of cells that undergo mitotic arrest is dictated by two competing networks activated by DYZ-2-90: the cytoprotective ERK pathway and the stress-related JNK pathway. DYZ-2-90 is therefore a novel microtubule-destabilizing agent and a new drug candidate for cancer therapy. This paper provides a new insight into the model of mitotic cell death, which was proposed in order to elucidate how cancer cells respond to microtubule-interfering agents and prolonged cell cycle delay.
在过去几十年中,人们对从传统中药中发现具有抗癌潜力的天然产物并通过化学修饰提高其抗癌选择性产生了浓厚的兴趣,这种兴趣持续增长。此外,从天然产物中全合成活性化合物可以克服资源可用性差的问题。DYZ-2-90 是一种从丹参中分离得到的新型开环化合物,是从中药丹参中分离得到的新型开环化合物。体外和体内微管聚合试验均表明,DYZ-2-90 直接与微管结合,迅速诱导微管解聚,通过 JNK 激活诱导 ERK 介导的有丝分裂停滞和随后的细胞凋亡。这些结果表明,经历有丝分裂停滞的细胞的命运由 DYZ-2-90 激活的两个竞争网络决定:细胞保护 ERK 途径和应激相关的 JNK 途径。因此,DYZ-2-90 是一种新型的微管去稳定剂,也是癌症治疗的一种新的候选药物。本文为有丝分裂细胞死亡模型提供了新的见解,该模型旨在阐明癌细胞如何对微管干扰剂和延长的细胞周期延迟做出反应。